An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

• Status: Terminated
• Trial end date: 2018-01-31
• Target enrollment: 0
• Participant gender: All

Summary

This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment groups also had an intra-patient dose titration (Part 2).

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Incyte Corporation
• Treatments: INCB054329

Criteria

Key Inclusion Criteria:

• Confirmed diagnosis of advanced malignancy:

• Treatment Group A (TGA): Part 1 and Part 2: Any advanced solid tumor or lymphoma; Part 3: Histologically confirmed disease in specific solid tumors and lymphomas

• Treatment Group B (TGB): Acute Leukemia (Part 3 - acute myeloid leukemia [AML] only), myelodysplastic syndrome (MDS), myelodysplastic /myeloproliferative neoplasms (MDS/MPN) and myelofibrosis (MF)

• Treatment Group C (TGC): Multiple myeloma

• Progressed following at least 1 line of prior therapy and there is no further approved therapy available that has been demonstrated to prolong survival (including subjects who are intolerant to the approved therapy)

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 in Parts 1 and 2 dose escalation and titration, and 0, 1, 2 in Part 3 dose expansion

Key Exclusion Criteria:

• Inadequate hematopoietic, liver, endocrine or renal function

• Receipt of anticancer medications or investigational drugs within the following interval before the first administration of study drug:

• < 6 weeks for mitomycin-C or nitrosoureas

• < 5 half-lives or 14 days, whichever is longer, for any investigational agent (for any indication)

• < 28 days for any antibodies or biological therapies

• < 5 half-lives for all other anticancer medications, or sponsor approval

• Prior radiotherapy within 2 weeks prior to first dose of study drug

• Untreated brain or central nervous system (CNS) metastases

• Type 1 diabetes or uncontrolled Type 2 diabetes

• Any sign of clinically significant bleeding